Anthony Patron

“Maybe one on depression and one on sleep. You have the 36-month data from Recover, I guess, getting ready to be submitted for publication. Just wanted to, you know, does CMS have the 36-month data for their consideration?”

“One on breast and one on prostate for the team here. Maybe on breast, you know, breaking out numbers here, you know, hitting an inflection point.”

“Maybe first, just on the competitive landscape as it sits today and just how it's going to evolve over time, do you think we're in a position to gain share, I guess, from scleral lenses, which is an option here ahead of corneal crosslinking.”

“Maybe Tim and Brian, you know, sort of a two-part question here. Asensia coming over in the U.S., you know, described as a seamless transition.”

“Please go ahead. uh thanks and um congratulations pete sandra and to the team on on a strong uh start to the year here you know maybe the uh the u.s momentum here it looks like an inflection and you have really you know almost two simultaneous launches if you will ongoing it's it's the u.s motiva platform in and of…”